perspective from Europe

Povzetek

A questionnaire on biomarker testing previously used in central European countries was extended and distributed in Western and Central European countries to the pathologists participating at the Pulmonary Pathology Society meeting 26-28 June 2019 in Dubrovnik, Croatia. Each country was represented by one responder. For recent biomarkers the availability and reimbursement of diagnoses of molecular alterations in non-small cell lung carcinoma varies widely between different, also western European, countries. Reimbursement of such assessments varies widely between unavailability and payments by the health care system or even pharmaceutical companies. The support for testing from alternative sources, such as the pharmaceutical industry, is no doubt partly compensating for the lack of public health system support, but it is not a viable or long-term solution. Ideally, a structured access to testing and reimbursement should be the aim in order to provide patients with appropriate therapeutic options. As biomarker enabled therapies deliver a 50% better probability of outcome success, improved and unbiased reimbursement remains a major challenge for the future.

Ključne besede

pljučni rak;napovedno testiranje;lung cancer;predictive testing;

Podatki

Jezik: Angleški jezik
Leto izida:
Tipologija: 1.02 - Pregledni znanstveni članek
Založnik: AME Publishing
UDK: 616-006
COBISS: 28071683 Povezava se bo odprla v novem oknu
ISSN: 2226-4477
Št. ogledov: 990
Št. prenosov: 659
Ocena: 0 (0 glasov)
Metapodatki: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Ostali podatki

Sekundarne ključne besede: Lung neoplasms;Diagnosis;Therapy;Europe;Pljučne novotvorbe;Diagnostika;Terapija;Evropa;
Komentar vira: Nasl. z nasl. zaslona; Soavtor iz Slovenije: Izidor Kern; Opis vira z dne 11. 9. 2020;
Strani: str. 887-897
Letnik: ǂVol. ǂ9
Zvezek: ǂiss. ǂ3
Čas izdaje: Jun. 2020
DOI: 10.21037/tlcr.2020.04.07
ID: 12036969
Priporočena dela:
, perspective from Europe
, ni podatka o podnaslovu
, ni podatka o podnaslovu
, ǂa ǂprecursor study in 35 countries